×
About 13,120 results

ALLMedicine™ Myelodysplastic Syndromes Center

Research & Reviews  6,241 results

Relationship between Low Pretreatment Geriatric Nutritional Risk Index and Poor Tolerab...
https://doi.org/10.1159/000513542
Annals of Nutrition & Metabolism; Kanehira D, Koinuma M et. al.

Mar 4th, 2021 - Predicting tolerability and treatment-related risks associated with azacitidine (AZA) in patients with myelodysplastic syndromes (MDS) before the initiation of therapy is required for appropriate treatment. Thus, in this study, the nutritional sta...

Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes:...
https://doi.org/10.1182/bloodadvances.2020003381
Blood Advances; Rozema J, Hoogendoorn M et. al.

Mar 3rd, 2021 - Population-based studies that contain detailed clinical data on patients with myelodysplastic syndrome (MDS) are scarce. This study focused on the real-world overall survival (OS) of MDS patients in association with comorbidities, specifically mal...

Hemophagocytic lymphohistiocytosis and myelodysplastic syndrome: a case report and revi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919086
Journal of Medical Case Reports; Sun Y, Blieden C et. al.

Mar 2nd, 2021 - Hemophagocytic lymphohistiocytosis (HLH) is characterized by hyperinflammation and life-threatening cytopenias. Survival is poor, and management is pivotal on rapid identification of the disease. HLH is associated with hematologic malignancies, ho...

Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host ...
https://doi.org/10.1136/jitc-2020-001818
Journal for Immunotherapy of Cancer; Saberian C, Abdel-Wahab N et. al.

Feb 27th, 2021 - Immune checkpoint inhibitors (ICIs) are being used after allogeneic hematopoietic stem cell transplantation (alloHCT) to reverse immune dysfunction. However, a major concern for the use of ICIs after alloHCT is the increased risk of graft-versus-h...

see more →

Guidelines  31 results

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment a...
https://doi.org/10.1016/j.annonc.2020.11.002
Annals of Oncology : Official Journal of the European Soc... Fenaux P, Haase D et. al.

Nov 22nd, 2020 - Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆.|2020|Fenaux P,Haase D,Santini V,Sanz GF,Platzbecker U,|diagnosis,epidemiology,therapy,

Considerable Variation Exists in Receipt of Complete Diagnostic Evaluations for Myelodysplastic Syndromes Among Medicare Patients
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200129/full/

May 12th, 2020 - A substantial proportion of Medicare patients with myelodysplastic syndromes (MDS) do not undergo a complete diagnostic evaluation (CDE), including a bone marrow biopsy, to confirm their disease (Abstract 7555).

Hematology Quality Metrics
http://www.hematology.org/Clinicians/Guidelines-Quality/503.aspx
Allen, S.

Feb 20th, 2018 - These clinical performance measures are designed for individual quality improvement. Some of the measures may also be appropriate for accountability if appropriate sample sizes and implementation rules are achieved.

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0007
Journal of the National Comprehensive Cancer Network : JN... Greenberg PL, Stone RM et. al.

Jan 3rd, 2017 - The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the p...

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from...
http://www.bloodjournal.org/content/122/17/2943
Malcovati, L.,et al.

Oct 23rd, 2013 - Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program. A systematic review of the lit.

see more →

Drugs  57 results see all →

Clinicaltrials.gov  6,495 results

Relationship between Low Pretreatment Geriatric Nutritional Risk Index and Poor Tolerab...
https://doi.org/10.1159/000513542
Annals of Nutrition & Metabolism; Kanehira D, Koinuma M et. al.

Mar 4th, 2021 - Predicting tolerability and treatment-related risks associated with azacitidine (AZA) in patients with myelodysplastic syndromes (MDS) before the initiation of therapy is required for appropriate treatment. Thus, in this study, the nutritional sta...

Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes:...
https://doi.org/10.1182/bloodadvances.2020003381
Blood Advances; Rozema J, Hoogendoorn M et. al.

Mar 3rd, 2021 - Population-based studies that contain detailed clinical data on patients with myelodysplastic syndrome (MDS) are scarce. This study focused on the real-world overall survival (OS) of MDS patients in association with comorbidities, specifically mal...

Hemophagocytic lymphohistiocytosis and myelodysplastic syndrome: a case report and revi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919086
Journal of Medical Case Reports; Sun Y, Blieden C et. al.

Mar 2nd, 2021 - Hemophagocytic lymphohistiocytosis (HLH) is characterized by hyperinflammation and life-threatening cytopenias. Survival is poor, and management is pivotal on rapid identification of the disease. HLH is associated with hematologic malignancies, ho...

Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host ...
https://doi.org/10.1136/jitc-2020-001818
Journal for Immunotherapy of Cancer; Saberian C, Abdel-Wahab N et. al.

Feb 27th, 2021 - Immune checkpoint inhibitors (ICIs) are being used after allogeneic hematopoietic stem cell transplantation (alloHCT) to reverse immune dysfunction. However, a major concern for the use of ICIs after alloHCT is the increased risk of graft-versus-h...

see more →

News  287 results

Myelodysplastic Syndromes Clinical Practice Guidelines (ESMO, 2021)
https://reference.medscape.com/viewarticle/944879

Feb 2nd, 2021 - Guidelines on the diagnosis and treatment of myelodysplastic syndromes were published in November 2020 by the European Society of Medical Oncology.[1] The diagnosis of myelodysplastic syndromes (MDS) is based on the blood count, the marrow aspirat...

FDA Approves Oral Therapy for Myelodysplastic Syndromes, CMML
https://www.medscape.com/viewarticle/933602

Jul 7th, 2020 - The Food and Drug Administration has approved Inqovi (decitabine and cedazuridine tablets, Astex Pharmaceuticals) to treat adults with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The agency's action gives physicians ...

Considerable Variation Exists in Receipt of Complete Diagnostic Evaluations for Myelodysplastic Syndromes Among Medicare Patients
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200129/full/

May 12th, 2020 - A substantial proportion of Medicare patients with myelodysplastic syndromes (MDS) do not undergo a complete diagnostic evaluation (CDE), including a bone marrow biopsy, to confirm their disease (Abstract 7555).

First Advance in MDS for Decade: Luspatercept for Anemia
https://www.medscape.com/viewarticle/928198

Apr 5th, 2020 - The US Food and Drug Administration (FDA) has approved luspatercept (Reblozyl, Bristol-Myers Squibb/Acceleron) for the treatment of anemia in patients with myelodysplastic syndromes (MDS). The green light represents the first treatment advancement...

Drug Reduces Need for Transfusions in Some Patients With Myelodysplastic Syndromes
https://www.medscape.com/viewarticle/923569

Jan 9th, 2020 - (Reuters Health) - Therapy every 3 weeks with the drug luspatercept dramatically reduced the need for blood transfusions in a subset of patients with lower-risk myelodysplastic syndromes (MDS), according to results from the MEDALIST study reported...

see more →

Patient Education  9 results see all →